Timberlyne Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Timberlyne Therapeutics's estimated annual revenue is currently $1.4M per year.
- Timberlyne Therapeutics's estimated revenue per employee is $140,000
Employee Data
- Timberlyne Therapeutics has 10 Employees.
Timberlyne Therapeutics's People
| Name | Title | Email/Phone |
|---|
What Is Timberlyne Therapeutics?
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for autoimmune diseases. We are leveraging the extensive drug development expertise of our team to acquire best-in-class assets against compelling targets, and applying them to disease areas with significant unmet need. Timberlyne’s lead program, CM313, is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38. By targeting CD38, highly expressed on plasma cells, NK cells, and other immune cells, CM313 can modulate multiple arms of the immune system leading to both rapid and durable responses across a range of autoimmune diseases. CM313 has been tested in numerous disease states including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma. Timberlyne plans to develop CM313 across a broad range of autoimmune indications. Launched in 2024, Timberlyne has raised $180 million from leading life sciences investors.
keywords:N/A
N/A
Total Funding
10
Number of Employees
$1.4M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.2M | 10 | -37% | N/A |
#2 | $1.2M | 10 | -41% | N/A |
#3 | $0.9M | 10 | N/A | N/A |
#4 | $1.5M | 10 | N/A | N/A |
#5 | $0.9M | 10 | N/A | N/A |